Details

Autor(en) / Beteiligte

• Huan, Hong-Bo
• Lau, Wan-Yee
• Xia, Feng
• Ma, Kuan-Sheng
• Bie, Ping

Titel

Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma

Ist Teil von

• World journal of gastroenterology : WJG, 2014-10, Vol.20 (39), p.14505-14509

Ort / Verlag

United States: Baishideng Publishing Group Inc

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• Partial hepatectomy is still the treatment of choice aiming at a cure for patients with hepatocellular carcinoma(HCC), provided that the patient can tolerate the treatment. For patients with multiple recurrent HCC after partial hepatectomy which cannot be treated by re-hepatectomy or local ablative therapy, the prognosis is extremely poor. sorafenib is a molecular-targeted agent which has been demonstrated in two global phase III randomized controlled trials to show survival benefit for advanced HCC. Here, we present a 56-yearold patient with HCC who showed complete clinical response after sorafenib was used for tumor recurrence which developed 3 mo after partial hepatectomy. There was no evidence of progression of disease for 60 mo till now after continuous treatment with sorafenib.